| Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects JE Allen, G Krigsfeld, PA Mayes, L Patel, DT Dicker, AS Patel, NG Dolloff, ... Science translational medicine 5 (171), 171ra17-171ra17, 2013 | 326 | 2013 |
| A Bayesian machine learning approach for drug target identification using diverse data types NS Madhukar, PK Khade, L Huang, K Gayvert, G Galletti, M Stogniew, ... Nature communications 10 (1), 5221, 2019 | 200 | 2019 |
| ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases CLB Kline, APJ Van den Heuvel, JE Allen, VV Prabhu, DT Dicker, ... Science signaling 9 (415), ra18-ra18, 2016 | 187 | 2016 |
| ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies JO Ishizawa, K Kojima, D Chachad, P Ruvolo, V Ruvolo, RO Jacamo, ... Science signaling 9 (415), ra17-ra17, 2016 | 178 | 2016 |
| Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201 AS Chi, RS Tarapore, MD Hall, N Shonka, S Gardner, Y Umemura, ... Journal of neuro-oncology 145 (1), 97-105, 2019 | 175 | 2019 |
| A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma I Arrillaga-Romany, AS Chi, JE Allen, W Oster, PY Wen, TT Batchelor Oncotarget 8 (45), 79298, 2017 | 158 | 2017 |
| First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors MN Stein, JR Bertino, HL Kaufman, T Mayer, R Moss, A Silk, N Chan, ... Clinical cancer research 23 (15), 4163-4169, 2017 | 152 | 2017 |
| Discovery and clinical introduction of first-in-class imipridone ONC201 JE Allen, CLB Kline, VV Prabhu, J Wagner, J Ishizawa, N Madhukar, ... Oncotarget 7 (45), 74380, 2016 | 146 | 2016 |
| Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem–like cells in an Akt/Foxo3a/TRAIL–dependent manner VV Prabhu, JE Allen, DT Dicker, WS El-Deiry Cancer research 75 (7), 1423-1432, 2015 | 139 | 2015 |
| ONC201 and imipridones: Anti-cancer compounds with clinical efficacy VV Prabhu, S Morrow, AR Kawakibi, L Zhou, M Ralff, J Ray, A Jhaveri, ... Neoplasia 22 (12), 725-744, 2020 | 125 | 2020 |
| Antibody-drug conjugates and methods AJ Ebens Jr, FS Jacobson, P Polakis, RH Schwall, MX Sliwkowski, ... US Patent 8,142,784, 2012 | 124 | 2012 |
| Regulation of the human TRAIL gene JE Allen, WS El-Deiry Cancer biology & therapy 13 (12), 1143-1151, 2012 | 116 | 2012 |
| Role of dopamine receptors in the anticancer activity of ONC201 CLB Kline, MD Ralff, AR Lulla, JM Wagner, PH Abbosh, DT Dicker, ... Neoplasia 20 (1), 80-91, 2018 | 115 | 2018 |
| Targeting TRAIL in the treatment of cancer: new developments B Lim, JE Allen, VV Prabhu, MK Talekar, NK Finnberg, WS El-Deiry Expert opinion on therapeutic targets 19 (9), 1171-1185, 2015 | 114 | 2015 |
| Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases AS Patel, JE Allen, DT Dicker, KL Peters, JM Sheehan, MJ Glantz, ... Oncotarget 2 (10), 752, 2011 | 101 | 2011 |
| Session-state manager J Allen US Patent 6,877,095, 2005 | 95 | 2005 |
| Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway JE Allen, G Krigsfeld, L Patel, PA Mayes, DT Dicker, GS Wu, WS El-Deiry Molecular cancer 14, 1-10, 2015 | 93 | 2015 |
| First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report MD Hall, Y Odia, JE Allen, R Tarapore, Z Khatib, TN Niazi, D Daghistani, ... Journal of Neurosurgery: Pediatrics 23 (6), 719-725, 2019 | 76 | 2019 |
| Metabolic reprogramming by dual AKT/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma CT Ishida, Y Zhang, E Bianchetti, C Shu, TTT Nguyen, G Kleiner, ... Clinical Cancer Research 24 (21), 5392-5406, 2018 | 75 | 2018 |
| Circulating tumor cells and colorectal cancer JE Allen, WS El-Deiry Current colorectal cancer reports 6, 212-220, 2010 | 73 | 2010 |
